Hypha Labs (FUNI) 10-Q 20 May 24 2024 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Mar. 31, 2024	May 20, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--09-30
Entity File Number	000-54239
Entity Registrant Name	Hypha Labs, Inc.
Entity Central Index Key	0001502966
Entity Tax Identification Number	27-3601979
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	5940 S. Rainbow Boulevard
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89118
City Area Code	(702)
Local Phone Number	527-2060
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		105,280,155

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Sep. 30, 2023
Current assets:
Cash	$ 1,063,401	$ 271,006
Note receivable, net of allowance of $625,000
Other current assets	321,943	8,570
Assets held for sale - current		486,222
Total current assets	1,385,344	765,798
Assets held for sale – long term		643,666
Total non-current assets		643,666
Total Assets	1,385,344	1,409,464
Current liabilities:
Accounts payable	102,140	122,094
Current maturities of notes payable		565,000
Liabilities held for sale - current		368,655
Total current liabilities	1,523,405	3,121,814
Non-current liabilities:
Liabilities held for sale – long term		159,156
Total non-current liabilities		159,156
Total Liabilities	1,523,405	3,280,970
Series B convertible preferred stock, $0.001 par value, 1,500,000 shares authorized; 333,600 shares issued and outstanding as of March 31, 2024 and September 30, 2023	333,600	333,600
Commitments and contingencies
Stockholders’ Deficit:
Common stock, $0.001 par value, 250,000,000 shares authorized; 105,280,155 and 87,096,820 shares issued and outstanding at March 31, 2024 and September 30, 2023, respectively	105,280	87,097
Additional paid-in capital	18,796,541	17,468,746
Accumulated deficit	(19,374,530)	(19,761,997)
Total Stockholders’ Deficit	(471,661)	(2,205,106)
Total Liabilities and Stockholders’ Deficit	1,385,344	1,409,464
Series A Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Preferred stock, value	1,048	1,048
Series C Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Preferred stock, value
Nonrelated Party [Member]
Current liabilities:
Accrued expenses – related party	323,030	328,491
Current maturities of convertible notes payable related parties, net of discounts	1,078,235	1,385,932
Related Party [Member]
Current liabilities:
Accrued expenses – related party	20,000	12,390
Current maturities of convertible notes payable related parties, net of discounts		$ 339,252

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2024	Sep. 30, 2023
Allowance for note receivable	$ 625,000	$ 625,000
Preferred stock, par value	$ 0.001
Preferred stock, shares authorized	10,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	105,280,155	87,096,820
Common stock, shares outstanding	105,280,155	87,096,820
Series B Convertible Preferred Stock [Member]
Temporary equity, par value	$ 0.001	$ 0.001
Temporary equity, shares authorized	1,500,000	1,500,000
Temporary equity, shares issued	333,600	333,600
Temporary equity, shares outstanding	333,600	333,600
Series A Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	6,000,000	6,000,000
Preferred stock, shares issued	1,047,942	1,047,942
Preferred stock, shares outstanding	1,047,942	1,047,942
Series C Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000	1,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenues
Cost of sales
Gross profit
Operating expenses:
General and administrative	182,504	45,674	197,247	85,198
Professional fees	391,543	128,440	447,364	175,637
Total operating expenses	574,047	174,114	644,611	260,835
Operating loss	(574,047)	(174,114)	(644,611)	(260,835)
Other income (expense):
Other Expense				(55,000)
Gain on sale of subsidiary assets	1,596,505		1,596,505
Recovery of previously written off receivables		135,000		135,000
Other income			13,896
Loss on debt extinguishment	(956,494)		(956,494)
Interest expense	(73,958)	(82,707)	(158,271)	(179,859)
Total other income (expense)	566,053	52,293	495,636	(99,859)
Net loss from continuing operations before income taxes	(7,994)	(121,821)	(148,975)	(360,694)
Provision for income taxes	48,714		48,714
Net loss from continuing operations	(56,708)	(121,821)	(197,689)	(360,694)
Net income from discontinued operations, net of taxes	292,529	54,323	585,156	52,866
Net income (loss)	$ 235,821	$ (67,498)	$ 387,467	$ (307,828)
Weighted average number of common shares outstanding – basic	92,083,084	82,296,820	89,576,328	82,257,534
Weighted average number of common shares outstanding – fully diluted	92,083,084	82,296,820	89,576,328	82,257,534
Net loss per share from continuing operations – basic	$ 0	$ 0	$ 0	$ 0
Net income (loss) per share from discontinued operations – basic	0	0	0.01	0
Net income (loss) per share – basic	0	0	0	0
Net loss per share from continuing operations – diluted	0	0	0	0
Net income (loss) per share from discontinued operations – diluted	0	0	0.01	0
Net income (loss) per share – diluted	$ 0	$ 0	$ 0	$ 0

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit (Unaudited) - USD ($)	Preferred Stock [Member] Series A Convertible Preferred Stock [Member]	Preferred Stock [Member] Series C Convertible Preferred Stock [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Stock Payable [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total	Series B Convertible Preferred Stock [Member]
Balance at Sep. 30, 2022	$ 1,048	$ 1		$ 75,147	$ 71,745	$ 17,117,958	$ (20,008,771)	$ (2,742,872)
Balance, shares at Sep. 30, 2022			333,600
Balance at Sep. 30, 2022			$ 333,600
Balance, shares at Sep. 30, 2022	1,047,942	1,000		75,146,820
Stock-based compensation						8,306		8,306
Stock-based compensation, shares
Net income (loss)							(240,330)	(240,330)
Issuance of common shares to settle stock payable				$ 7,150	(71,745)	64,595
Issuance of common shares to settle stock payable, shares				7,150,000
Warrants issued as debt financing costs						93,938		93,938
Balance at Dec. 31, 2022	$ 1,048	$ 1		$ 82,297		17,284,797	(20,249,101)	(2,880,958)
Balance, shares at Dec. 31, 2022			333,600
Balance at Dec. 31, 2022			$ 333,600
Balance, shares at Dec. 31, 2022	1,047,942	1,000		82,296,820
Balance at Sep. 30, 2022	$ 1,048	$ 1		$ 75,147	71,745	17,117,958	(20,008,771)	(2,742,872)
Balance, shares at Sep. 30, 2022			333,600
Balance at Sep. 30, 2022			$ 333,600
Balance, shares at Sep. 30, 2022	1,047,942	1,000		75,146,820
Net income (loss)								(307,828)
Balance at Mar. 31, 2023	$ 1,048			$ 82,297	32,120	17,293,902	(20,316,599)	(2,907,232)
Balance, shares at Mar. 31, 2023			333,600
Balance at Mar. 31, 2023			$ 333,600
Balance, shares at Mar. 31, 2023	1,047,942			82,296,820
Balance at Dec. 31, 2022	$ 1,048	$ 1		$ 82,297		17,284,797	(20,249,101)	(2,880,958)
Balance, shares at Dec. 31, 2022			333,600
Balance at Dec. 31, 2022			$ 333,600
Balance, shares at Dec. 31, 2022	1,047,942	1,000		82,296,820
Stock-based compensation						9,204		9,204
Stock-based compensation, shares
Net income (loss)							(67,498)	(67,498)
Repurchased of preferred C stock		$ (1)		$ 0	0	(99)		(100)
Repurchased of preferred C stock, shares		(1,000)		0
Common shares to be issued for compensation					32,120			32,120
Balance at Mar. 31, 2023	$ 1,048			$ 82,297	32,120	17,293,902	(20,316,599)	(2,907,232)
Balance, shares at Mar. 31, 2023			333,600
Balance at Mar. 31, 2023			$ 333,600
Balance, shares at Mar. 31, 2023	1,047,942			82,296,820
Balance at Sep. 30, 2023	$ 1,048			$ 87,097		17,468,746	(19,761,997)	(2,205,106)
Balance, shares at Sep. 30, 2023			333,600						333,600
Balance at Sep. 30, 2023			$ 333,600					333,600
Balance, shares at Sep. 30, 2023	1,047,942			87,096,820
Stock-based compensation						1,153		1,153
Stock-based compensation, shares
Net income (loss)							151,646	151,646
Balance at Dec. 31, 2023	$ 1,048			$ 87,097		17,469,899	(19,610,351)	(2,052,307)
Balance, shares at Dec. 31, 2023			333,600
Balance at Dec. 31, 2023			$ 333,600
Balance, shares at Dec. 31, 2023	1,047,942			87,096,820
Balance at Sep. 30, 2023	$ 1,048			$ 87,097		17,468,746	(19,761,997)	(2,205,106)
Balance, shares at Sep. 30, 2023			333,600						333,600
Balance at Sep. 30, 2023			$ 333,600					333,600
Balance, shares at Sep. 30, 2023	1,047,942			87,096,820
Stock-based compensation, shares				14,183,335
Net income (loss)								387,467
Issuance of common shares to settle stock payable				$ 40,000
Issuance of common shares to settle stock payable, shares				4,000,000
Balance at Mar. 31, 2024	$ 1,048			$ 105,280		18,796,541	(19,374,530)	(471,661)
Balance, shares at Mar. 31, 2024		0	333,600						333,600
Balance at Mar. 31, 2024			$ 333,600					333,600
Balance, shares at Mar. 31, 2024	1,047,942			105,280,155
Balance at Dec. 31, 2023	$ 1,048			$ 87,097		17,469,899	(19,610,351)	(2,052,307)
Balance, shares at Dec. 31, 2023			333,600
Balance at Dec. 31, 2023			$ 333,600
Balance, shares at Dec. 31, 2023	1,047,942			87,096,820
Stock-based compensation				$ 14,183		334,148		348,331
Stock-based compensation, shares				14,183,335
Net income (loss)							235,821	235,821
Shares issued for conversion of notes payable				$ 4,000		36,000		40,000
Balance, shares				4,000,000
Modification of conversion price in debt extinguishment						956,494		956,494
Balance at Mar. 31, 2024	$ 1,048			$ 105,280		$ 18,796,541	$ (19,374,530)	(471,661)
Balance, shares at Mar. 31, 2024		0	333,600						333,600
Balance at Mar. 31, 2024			$ 333,600					$ 333,600
Balance, shares at Mar. 31, 2024	1,047,942			105,280,155

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023	Sep. 30, 2023
Cash flows from operating activities
Net loss from continuing operations			$ (197,689)	$ (360,694)
Adjustments to reconcile net loss to net cash used in operating activities:
Recovery of previously written off receivables		$ (135,000)		(135,000)
Gain on sale of subsidiary net assets	(1,596,505)		(1,596,505)
Loss on debt extinguishment	956,494		956,494
Stock-based compensation			349,484	49,630
Amortization of debt discounts			43,050	77,616
Impairment of fixed assets				55,000
Decrease (increase) in assets:
Other current assets			(3,030)	1,289
Increase (decrease) in liabilities:
Accounts payable			(14,530)	33,384
Accrued expenses			20,080	(16,253)
Accrued expenses – related parties			7,610	12,000
Net cash used in operating activities from continuing operations			(435,036)	(283,028)
Net cash provided by operating activities from discontinued operations			373,913	141,538
Net cash used in operating activities			(61,123)	(141,490)
Cash flows from investing activities
Cash received from sale of subsidiary net assets			2,126,934
Proceeds from sale of collateralized assets				235,000
Net cash provided by investing activities from continuing operations			2,126,934	235,000
Net cash used in investing activities from discontinued operations			(11,667)	(3,687)
Net cash provided by investing activities			2,115,267	231,313
Cash flows from financing activities
Repayments of notes payable			(595,965)
Repayments of convertible notes payable			(650,000)
Repurchase of Preferred C stock				(100)
Net cash used in financing activities from continuing operations			(1,245,965)	(100)
Net cash used in financing activities from discontinued operations			(15,784)	(30,023)
Net cash used in financing activities			(1,261,749)	(30,123)
Net increase in cash			792,395	59,700
Cash – beginning			271,006	56,168	$ 56,168
Cash – ending	$ 1,063,401	$ 115,868	1,063,401	115,868	$ 271,006
Supplemental disclosures:
Interest paid			126,533	151,927
Income taxes paid
Non-cash investing and financing activities:
Common stock issued for settlement of stock payable				71,745
Warrants issued for debt financing				93,938
Accounts payable and accrued interest added to note principal balance			30,965
Common stock issued for conversion of note payable			$ 40,000

Nature of Business and Signific

Nature of Business and Significant Accounting Policies	6 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Nature of Business and Significant Accounting Policies	Note 1 – Nature of Business and Significant Accounting Policies Nature of Business Hypha Labs, Inc. (formerly Digipath, Inc.) was incorporated in Nevada on October 5, 2010. Until February 20, 2024, Hypha Labs, Inc. and its subsidiaries (“Hypha,” the “Company,” “we,” “our” or “us”) was a service-oriented independent testing laboratory, data analytics and media firm focused on the developing cannabis and hemp markets, and supported the cannabis industry’s best practices for reliable testing, cannabis education and training. Our mission was to provide pharmaceutical-grade analysis and testing to the cannabis industry, under ISO-17025:2017 guidelines, to ensure consumers and patients knew exactly what was in the cannabis they ingest and to help maximize the quality of our clients’ products through research, development, and standardization. Hypha Labs had been operating a cannabis-testing lab in Nevada since 2015. On February 20, 2024, we completed the sale of the net assets of our subsidiary Digipath Labs, Inc. (“Digipath Labs”). As of that date we were no longer in the business as a service-oriented independent testing laboratory, data analytics and media firm focused on the developing cannabis and hemp markets, which supported the cannabis industry’s best practices for reliable testing, cannabis education and training. Effective March 12, 2024, the Company amended Article 1 of its Articles of Incorporation to change its name from Digipath, Inc. to Hypha Labs, Inc. Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Intercompany accounts and transactions have been eliminated. The unaudited condensed consolidated financial statements of the Company and the accompanying notes included in this Quarterly Report on Form 10-Q are unaudited. In the opinion of management, all adjustments necessary for a fair presentation of the Condensed Consolidated Financial Statements have been included. Such adjustments are of a normal, recurring nature. The Condensed Consolidated Financial Statements, and the accompanying notes, are prepared in accordance with GAAP and do not contain certain information included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2023. The interim Condensed Consolidated Financial Statements should be read in conjunction with that Annual Report on Form 10-K. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year. Principles of Consolidation The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at March 31, 2024: Schedule of Entities Under Common Control and Ownership Jurisdiction of Name of Entity Incorporation Relationship Hypha Labs, Inc.(formerly Digipath, Inc.) (1) Nevada Parent Digipath Labs, Inc. Nevada Subsidiary Digipath Labs CA, Inc. (2) California Subsidiary Digipath Labs S.A.S. (3) Colombia Subsidiary VSSL Enterprises, Ltd. (4) Canada Subsidiary (1) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Hypha Labs, Inc., the parent company. (2) Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations. (3) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations. (4) Acquired on March 11, 2020. The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company and subsidiaries will be collectively referred to herein as the “Company”, “Hypha” or “DIGP”. The Company’s headquarters are located in Las Vegas, Nevada and substantially all of its customers were within the United States. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. Revenue Recognition The Company recognizes revenue in accordance with ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. Our revenue was primarily generated through our subsidiary, Digipath Labs which recognized revenue from the analytical testing of cannabis products for licensed producers and cultivators within the state of Nevada on a determinable fixed fee per test, or panel of tests, basis. Revenue from the performance of those services was recognized upon completion of the tests, at which time test results are delivered to the customer, provided collectability of the fee is reasonably assured. We typically require payment within thirty days of the delivery of results. For the three and six months ended March 31, 2024 and 2023, all revenues are classified as part of Net income from discontinued operations Discontinued Operations On April 20, 2023, the Company and Digipath Labs entered into an Asset Purchase Agreement (the “Purchase Agreement”) with DPL NV, LLC (“Buyer”), pursuant to which Digipath Labs agreed to sell substantially all of its assets to Buyer for a cash purchase price of $ 2,300,000 Assets and liabilities of the discontinued operations are aggregated and reported separately as assets and liabilities of discontinued operations in the Consolidated Balance Sheet as of September 30, 2023. On February 20, 2024, we completed the sale of the net assets of our subsidiary Digipath Labs and as such no longer have assets or liabilities that are reported separately in the Consolidated Balance Sheet as of March 31, 2024. The results of discontinued operations are aggregated and presented separately in the Consolidated Statements of Operations as net income from discontinued operations for the periods ended March 31, 2024 and 2023. The cash flows of the discontinued operations are reflected as cash flows of discontinued operations within the Company’s Consolidated Statements of Cash Flows for the periods ended March 31, 2024 and 2023. Amounts presented in discontinued operations have been derived from our consolidated financial statements and accounting records using the historical basis of assets, liabilities, results of operations, and cash flows of Digipath Labs. The discontinued operations exclude general corporate allocations. Basic and Diluted Loss Per Share The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. The following table presents the effect of potential dilutive issuances for the three and six months ended March 31, 2024 and 2023: Schedule of Effect of Potential Dilutive Issuances March 31, 2024 March 31, 2023 March 31, 2024 March 31, 2023 Three Months Ended Six Months Ended March 31, 2024 March 31, 2023 March 31, 2024 March 31, 2023 Net income (loss) attributable to common stockholders $ (56,708 ) $ (121,821 ) $ (197,689 ) $ (360,694 ) Interest expense associated with convertible debt - - - - Net income (loss) for dilutive calculation $ (56,708 ) $ (121,821 ) (197,689 ) (360,694 ) Weighted average shares outstanding 92,083,084 82,296,820 89,576,328 82,257,534 Dilutive effect of preferred stock - - - - Dilutive effect of convertible debt - - - - Dilutive effect of common stock warrants - - - - Weighted average shares outstanding for diluted net income (loss) per share 92,083,084 82,296,820 89,576,328 82,257,534 For the three and six months ended March 31, 2024, potential dilutive securities of 104,490,131 8,120,000 15,387,050 13,579,710 For the three and six months ended March 31, 2023, potential dilutive securities of 83,125,488 shares issuable upon conversion of convertible notes payable, 6,020,000 15,387,050 shares issuable upon exercise of warrants, and 13,579,710 shares issuable upon conversion of our Preferred A and Preferred B shares, respectively, had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share. Reclassifications Certain reclassifications have been made to the prior period financial statements to conform to the current period presentation. These reclassifications had no effect on our previously reported results of operations or accumulated deficit. Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07 Segment Reporting ( Topic 280 Improvements to Reportable Segment Disclosures, In December 2023, the FASB issued ASU 2023-09 Income Taxes ( Topic 740 Improvements to Income Tax Disclosures,

Going Concern

Going Concern	6 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 2 – Going Concern As shown in the accompanying consolidated financial statements, as of March 31, 2024, the Company had negative working capital of $ 138,061 19,374,530 1,063,401 The consolidated financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. These financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 3 – Fair Value of Financial Instruments Under FASB ASC 820-10-5, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under GAAP, certain assets and liabilities must be measured at fair value, and FASB ASC 820-10-50 details the disclosures that are required for items measured at fair value. The Company has certain financial instruments that must be measured under the new fair value standard. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of March 31, 2024 and September 30, 2023, respectively: Summary of Financial Instruments at Fair Value on Recurring Basis Level 1 Level 2 Level 3 Fair Value Measurements at March 31, 2024 Level 1 Level 2 Level 3 Assets Cash $ 1,063,401 $ - $ - Liabilities Convertible notes payable, net of discounts of $ 0 - - 1,078,235 Level 1 Level 2 Level 3 Fair Value Measurements at September 30, 2023 Level 1 Level 2 Level 3 Assets Cash $ 271,006 $ - $ - Liabilities Notes payable - 565,000 - Convertible notes payable, net of discounts of $ 43,051 - - 1,725,184 There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the six months ended March 31, 2024.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Mar. 31, 2024
Related Party Transactions [Abstract]
Related Party Transactions	Note 4 – Related Party Transactions During the six months ended March 31, 2024 the Company incurred compensation expense of $ 30,000 During the six months ended March 31, 2024 the Company accrued fees of $ 10,000 20,000

Note Receivable

Note Receivable	6 Months Ended
	Mar. 31, 2024
Receivables [Abstract]
Note Receivable	Note 5 – Note Receivable On various dates between December 28, 2018 and June 13, 2019, we loaned Northwest Analytical Labs, Inc. a total of $ 95,000 10 On various dates between August 23, 2021 and September 30, 2022, we loaned C3 Labs, Inc. (“C3 Labs”) a total of $ 1,056,570 8 64,017 The loans were made in connection with a potential acquisition of a controlling interest in C3 Labs pursuant to a letter of intent. On March 11, 2022, the Company notified the current owners of C3 Labs of its termination of the letter of intent and took possession of the equipment of C3 Labs (“C3 Equipment”). On December 8, 2022, the Company entered into an Asset Purchase Agreement with Invictus Wealth Group (“Invictus”), whereby the Company agreed to sell the C3 Equipment to Invictus for a total purchase price of $ 900,000 275,000 625,000 December 31, 2023 10 100,000 425,000 275,000 100,000 425,000 50,000 100,000 125,000 216,780 The Company recorded a full allowance against the Invictus Note, as of the transaction date, as collectability was not reasonably assured at of the transaction date.

Notes Payable

Notes Payable	6 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Notes Payable	Note 6 – Notes Payable Notes payable consists of the following at March 31, 2024 and September 30, 2023, respectively: Schedule of Notes Payable March 31, 2024 September 30, 2023 On September 10, 2021, the Company issued a Secured Promissory note in the principal amount of $ 675,000 12 September 10, 2024 22,419.66 115,000 100,000 125,000 35,965 $ - $ 565,000 Total notes payable - 565,000 Less: current maturities - (565,000 ) Notes payable $ - $ - The Company recorded interest expense pursuant to the stated interest rate and closing costs on the notes payable in the amount of $ 36,614 24,000 Notes payable – discontinued operations On December 26, 2019, the Company financed the purchase of $ 377,124 291,931 5.75 5,622 five-year December 26, 2024 $ - $ 80,428

Convertible Notes Payable

Convertible Notes Payable	6 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Convertible Notes Payable	Note 7 – Convertible Notes Payable Related party convertible notes payable consist of the following at March 31, 2024 and September 30, 2023, respectively: Schedule of Related Party Convertible Notes Payable March 31, 2024 September 30, 2023 On February 10, 2020, the Company completed the sale to an accredited investor of a 9% Secured Convertible Promissory Note in the principal amount of $ 350,000 August 10, 2022 9 0.15 0.03 50,000 400,000 50,000 1,666,667 0.03 February 11, 2024 4,550,000 43,788 As a result of the shares issued upon the extension agreement, the lender now holds more the 5% of the total outstanding common shares, and is therefore considered a related party $ - $ 350,000 Total related party convertible notes payable - 350,000 Less: unamortized debt discounts - (10,748 ) Total convertible debt - 339,252 Less: current maturities - (339,252 ) Related party convertible notes payable $ - $ - Convertible notes payable consist of the following at March 31, 2024 and September 30, 2023, respectively: Schedule of Convertible Notes Payable March 31, 2024 September 30, 2023 On February 11, 2020, the Company completed the sale to an accredited investor of a 9% Secured Convertible Promissory Note in the principal amount of $ 50,000 August 11, 2022 9 0.15 0.03 10,000 60,000 10,000 333,334 0.03 February 11, 2024 650,000 6,989 $ 50,000 $ 50,000 On February 11, 2020, the Company completed the sale to an accredited investor of a 9% Secured Subordinated Convertible Promissory Note in the principal amount of $ 150,000 August 11, 2022 9 0.15 0.03 50,000 200,000 50,000 1,666,667 0.03 February 11, 2024 1,950,000 20,968 - 150,000 On September 23, 2019, the Company received proceeds of $ 200,000 8 August 10, 2022 0.11 August 10, 2022 0.03 90,000 3,000,000 0.03 355,469 98,188 February 11, 2024 4,621,105 32,166 February 11, 2025 0.01 481,955 355,469 355,469 On November 8, 2018, the Company received proceeds of $ 350,000 8 August 10, 2022 0.14 August 10, 2022 0.03 February 11, 2024 4,550,000 31,671 40,000 February 11, 2025 0.01 474,539 310,000 350,000 On October 1, 2022, the Company entered into a senior secured convertible note that carries an 8 February 11, 2024 362,765 0.01 4,715,945 30,102 362,765 362,765 On November 5, 2018, the Company received proceeds of $ 150,000 8 August 10, 2022 0.14 August 10, 2022 0.03 - 150,000 Total convertible notes payable 1,078,235 1,418,234 Less: unamortized debt discounts - (32,302 ) Total convertible debt 1,078,235 1,385,932 Less: current maturities (1,078,235 ) (1,385,932 ) Convertible notes payable $ - $ - In addition, the Company recognized and measured the embedded beneficial conversion feature present in the convertible notes by allocating a portion of the proceeds equal to the intrinsic value of the feature to additional paid-in-capital. The intrinsic value of the feature was calculated on the commitment date using the effective conversion price of the convertible notes. This intrinsic value is limited to the portion of the proceeds allocated to the convertible debt. The aforementioned accounting treatment resulted in a total debt discount equal to $ 93,938 43,050 77,616 0 All of the convertible notes (except the related party convertible note) limit the maximum number of shares that can be owned by each note holder as a result of the conversions to common stock to 4.99 The Company recorded interest expense pursuant to the stated interest rates on the convertible notes in the amount of $ 77,808 72,473 The Company recognized interest expense for the six months ended March 31, 2024 and 2023, respectively, as follows: Schedule of Interest Expense March 31, 2024 March 31, 2023 Interest on notes payable 36,614 29,770 Amortization of beneficial conversion features 43,050 77,616 Interest on convertible notes 78,607 72,473 Total interest expense $ 158,271 $ 179,859

Stockholders_ Equity

Stockholders’ Equity	6 Months Ended
	Mar. 31, 2024
Equity [Abstract]
Stockholders’ Equity	Note 8 – Stockholders’ Equity Preferred Stock The Company is authorized to issue 10,000,000 0.001 6,000,000 1,500,000 1,000 2,499,000 1,047,942 333,600 no Series A The conversion price is adjustable in the event of stock splits and other adjustments in the Company’s capitalization, and in the event of certain negative actions undertaken by the Company. At the current conversion price, the 1,047,942 5,239,710 No holder is permitted to convert its shares of Series A Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice. Additional terms of the Series A Preferred include the following: ● The shares of Series A Preferred are entitled to dividends when, as and if declared by the Board as to the shares of the common stock of the Company into which such Series A Preferred may then be converted, subject to the 4.99 ● Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, the shares of Series A Preferred are entitled to receive, prior to any distribution to the holders of common stock, 100 ● The Series A Preferred plus all declared but unpaid dividends thereon automatically will be converted into common stock, at the then applicable conversion rate, upon the affirmative vote of the holders of a majority of the outstanding shares of Series A Preferred. ● Each share of Series A Preferred will carry a number of votes equal to the number of shares of common stock into which such Series A Preferred may then be converted, subject to the 4.99 ● Consent of the holders of the outstanding Series A Preferred, voting separately as a class, is required in order for the Company to: (i) amend or change the rights, preferences, privileges or powers of, or the restrictions provided for the benefit of, the Series A Preferred; (ii) authorize, create or issue shares of any class of stock having rights, preferences, privileges or powers superior to the Series A Preferred; (iii) reclassify any outstanding shares into shares having rights, preferences, privileges or powers superior to the Series A Preferred; or (iv) amend the Company’s Articles of Incorporation or Bylaws in a manner that adversely affects the rights of the Series A Preferred. ● Pursuant to various Securities Purchase Agreements, holders of Series A Preferred are entitled to unlimited “piggyback” registration rights on registrations by the Company, subject to pro rata cutback at any underwriter’s discretion. Series C The shares of Series C Preferred were designated on July 20, 2022 and each share has a Stated Value of $ 1 the Company’s common stock on all matters presented to the holders of common stock, whether at a special or annual meeting, by written action in lieu of a meeting or otherwise, on the basis of 200,000 votes for each share of Series C Preferred Stock 0.10 Additional terms of the Series C Preferred include the following: ● The shares of Series C Preferred are not entitled to dividends. ● Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, or upon a change in control whereby a stockholder gains control of 50% or more of the outstanding shares of common stock, the shares of Series C Preferred are entitled to receive, prior to any distribution to the holders of common stock, 100% of the stated value per share of Series C Preferred. ● The shares of Series C Preferred have no conversion rights. Common Stock The Company has 250,000,000 0.001 105,280,155 During the six months ended March 31, 2024, the Company issued 4,000,000 40,000 During the six months ended March 31, 2024, the Company issued 14,183,335 6,000,000 348,331 112,200

Mezzanine Equity

Mezzanine Equity	6 Months Ended
	Mar. 31, 2024
Mezzanine Equity
Mezzanine Equity	Note 9 – Mezzanine Equity Series B The shares of Series B Preferred were designated on December 29, 2021. Each share of Series B Preferred has a Stated Value of $ 1.00 0.04 333,600 8,340,000 No holder is permitted to convert its shares of Series B Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice Additional terms of the Series B Preferred include the following: ● The shares of Series B Preferred are not entitled to dividends, provided that if dividends are paid on the shares of common stock of the Company, the Series B Preferred will be entitled to dividends based on the number of shares of common stock into which the Series B Preferred may then be converted. ● Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, or upon a change in control whereby a stockholder gains control of 50% or more of the outstanding shares of common stock, the shares of Series B Preferred are entitled to receive, prior to any distribution to the holders of common stock and Series A Preferred, 100% of the purchase price per share of Series B Preferred plus all accrued but unpaid dividends ● Each share of Series B Preferred carries a number of votes equal to the number of shares of common stock into which such shares of Series B Preferred may then be converted. Due to the change in control provision of the Series B Preferred, the Series B Preferred is classified as temporary equity on the balance sheet.

Common Stock Options

Common Stock Options	6 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Common Stock Options	Note 10 – Common Stock Options Stock Incentive Plan On June 21, 2016, we amended and restated our 2012 Stock Incentive Plan (the “2012 Plan”), which was originally adopted on March 5, 2012, and terminated on March 5, 2022. As amended, the 2012 Plan provided for the issuance of up to 11,500,000 Amortization of Stock-Based Compensation A total of $ 1,153 17,510 no The following is a summary of information about the stock options outstanding at March 31, 2024. Summary of Common Stock Options Outstanding Shares Underlying Options Outstanding Shares Underlying Options Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Options Contractual Exercise Options Exercise Prices Outstanding Life Price Exercisable Price $ 0.0056 0.13 8,120,000 4.53 $ 0.052 8,120,000 $ 0.052 The following is a summary of activity of outstanding common stock options: Schedule of Activity of Outstanding Common Stock Options Weighted Average Number Exercise of Shares Price Balance, September 30, 2023 8,120,000 $ 0.052 Options issued - - Options forfeited - - Balance, March 31, 2024 8,120,000 $ 0.052 Exercisable, March 31, 2024 8,120,000 $ 0.052 As of March 31, 2024, these options in the aggregate had $ 33,600 0.022

Common Stock Warrants

Common Stock Warrants	6 Months Ended
	Mar. 31, 2024
Common Stock Warrants
Common Stock Warrants	Note 11 – Common Stock Warrants Warrants to purchase a total of 15,387,050 The following is a summary of information about our warrants to purchase common stock outstanding at March 31, 2024 (including those issued to both investors and service providers). Summary of Common Stock Warrants Outstanding Shares Underlying Warrants Outstanding Shares Underlying Warrants Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Warrants Contractual Exercise Warrants Exercise Prices Outstanding Life Price Exercisable Price $ 0.0074 0.10 15,387,050 8.26 $ 0.016 15,387,050 $ 0.016 The following is a summary of activity of outstanding common stock warrants: Schedule of Outstanding Common Stock Warrants Activity Weighted Average Number Exercise of Shares Price Balance, September 30, 2023 15,387,050 $ 0.016 Warrants granted - - Warrants expired - - Balance, March 31, 2024 15,387,050 $ 0.016 Exercisable, March 31, 2024 15,387,050 $ 0.016 As of March 31, 2024, these warrants in the aggregate had $ 197,196 0.02

Discontinued Operations

Discontinued Operations	6 Months Ended
	Mar. 31, 2024
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Note 12 – Discontinued Operations On April 20, 2023, the Company and Digipath Labs entered into the Purchase Agreement with DPL NV, LLC (“Buyer”), pursuant to which Digipath Labs has agreed to sell substantially all of its assets to Buyer for a cash purchase price of $ 2,300,000 150,000 The Purchase Agreement includes a number of representations, warrantees, covenants and conditions to closing customary for this type of transaction. In addition, the closing of the transaction was subject to the approval of the Nevada Cannabis Compliance Board (the “CCB”). On January 18, 2024, the Company received approval from the CCB to transfer the assets pursuant to the Purchase Agreement. Pursuant to the Purchase Agreement, the Buyer deposited $ 230,000 In connection with the transactions contemplated by the Purchase Agreement, Digipath, Digipath Labs and Buyer entered into a Management Services Agreement (the “Management Services Agreement”), dated as of April 30, 2023, pursuant to which Buyer was engaged to manage the operation of Digipath Labs’ cannabis testing laboratory (the “Lab”). The effectiveness of the Management Services Agreement was subject to the approval of the CCB, which was obtained on October 17, 2023. Pursuant to the Management Services Agreement, after the payment of expenses to third parties and a payment of 15% of cash collections to Digipath (but not less than $15,000) in each month, Buyer was entitled to a management fee of $10,000 per month. Any remaining cash generated from the operation of the Lab in any month was payable 45% to the Buyer and 55% to the Company. On February 20, 2024, we completed the sale of the net assets of our subsidiary Digipath Labs to Buyer. As a result of the closing, the Company recognized a gain on the sale of the net assets in the amount of $ 1,596,505 The balance sheets of Digipath Labs are summarized below: Schedule of Discontinued Operations of Income Statement and Balance Sheet Disclosures March 31, 2024 September 30, 2023 Current assets: Accounts receivable, net $ - $ 447,410 Deposits - 18,675 Other current assets - 20,137 Total current assets - 486,222 Right-of-use asset - 274,985 Fixed assets, net - 368,681 Total long term assets - 643,666 Total Assets $ - $ 1,129,888 Current liabilities: Accounts payable $ - $ 158,869 Accrued expenses - 61,512 Current portion of operating lease liabilities - 83,757 Current maturities of notes payable - 64,517 Total current liabilities - 368,655 Operating lease liabilities - 143,245 Notes payable - 15,911 Total long term liabilities - 159,156 Total Liabilities $ - $ 527,811 The statements of operations of Digipath Labs combined are summarized below: 2024 2023 2024 2023 For the Three Months Ended For the Six Months Ended March 31, March 31 2024 2023 2024 2023 Revenues $ 712,145 $ 760,710 $ 1,635,299 $ 1,487,465 Cost of sales 229,013 459,608 650,524 882,443 Gross profit 483,132 301,102 984,775 605,022 Operating expenses: General and administrative 189,983 224,346 393,168 504,990 Professional fees - 20,688 4,750 43,460 Total operating expenses 189,983 245,034 397,918 548,450 Operating income(loss) 293,149 56,068 586,857 56,572 Other income (expense): Interest expense (620 ) (1,745 ) (1,701 ) (3,706 ) Total other income (expense) (620 ) (1,745 ) (1,701 ) (3,706 ) Net income (loss) $ 292,529 $ 54,323 $ 585,156 $ 52,866

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 13 – Commitments and Contingencies Legal Contingencies There are no material pending legal proceedings to which we are a party or to which any of our property is subject, nor are there any such proceedings known to be contemplated by governmental authorities. None of our directors, officers or affiliates is involved in a proceeding adverse to our business or has a material interest adverse to our business.

Subsequent Events

Subsequent Events	6 Months Ended
	Mar. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	Note 14 – Subsequent Events Management has evaluated events through May 20, 2024, the date these financial statements were available for issuance, and noted no events requiring disclosures.

Nature of Business and Signif_2

Nature of Business and Significant Accounting Policies (Policies)	6 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Nature of Business	Nature of Business Hypha Labs, Inc. (formerly Digipath, Inc.) was incorporated in Nevada on October 5, 2010. Until February 20, 2024, Hypha Labs, Inc. and its subsidiaries (“Hypha,” the “Company,” “we,” “our” or “us”) was a service-oriented independent testing laboratory, data analytics and media firm focused on the developing cannabis and hemp markets, and supported the cannabis industry’s best practices for reliable testing, cannabis education and training. Our mission was to provide pharmaceutical-grade analysis and testing to the cannabis industry, under ISO-17025:2017 guidelines, to ensure consumers and patients knew exactly what was in the cannabis they ingest and to help maximize the quality of our clients’ products through research, development, and standardization. Hypha Labs had been operating a cannabis-testing lab in Nevada since 2015. On February 20, 2024, we completed the sale of the net assets of our subsidiary Digipath Labs, Inc. (“Digipath Labs”). As of that date we were no longer in the business as a service-oriented independent testing laboratory, data analytics and media firm focused on the developing cannabis and hemp markets, which supported the cannabis industry’s best practices for reliable testing, cannabis education and training. Effective March 12, 2024, the Company amended Article 1 of its Articles of Incorporation to change its name from Digipath, Inc. to Hypha Labs, Inc.
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Intercompany accounts and transactions have been eliminated. The unaudited condensed consolidated financial statements of the Company and the accompanying notes included in this Quarterly Report on Form 10-Q are unaudited. In the opinion of management, all adjustments necessary for a fair presentation of the Condensed Consolidated Financial Statements have been included. Such adjustments are of a normal, recurring nature. The Condensed Consolidated Financial Statements, and the accompanying notes, are prepared in accordance with GAAP and do not contain certain information included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2023. The interim Condensed Consolidated Financial Statements should be read in conjunction with that Annual Report on Form 10-K. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at March 31, 2024: Schedule of Entities Under Common Control and Ownership Jurisdiction of Name of Entity Incorporation Relationship Hypha Labs, Inc.(formerly Digipath, Inc.) (1) Nevada Parent Digipath Labs, Inc. Nevada Subsidiary Digipath Labs CA, Inc. (2) California Subsidiary Digipath Labs S.A.S. (3) Colombia Subsidiary VSSL Enterprises, Ltd. (4) Canada Subsidiary (1) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Hypha Labs, Inc., the parent company. (2) Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations. (3) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations. (4) Acquired on March 11, 2020. The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company and subsidiaries will be collectively referred to herein as the “Company”, “Hypha” or “DIGP”. The Company’s headquarters are located in Las Vegas, Nevada and substantially all of its customers were within the United States. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. Our revenue was primarily generated through our subsidiary, Digipath Labs which recognized revenue from the analytical testing of cannabis products for licensed producers and cultivators within the state of Nevada on a determinable fixed fee per test, or panel of tests, basis. Revenue from the performance of those services was recognized upon completion of the tests, at which time test results are delivered to the customer, provided collectability of the fee is reasonably assured. We typically require payment within thirty days of the delivery of results. For the three and six months ended March 31, 2024 and 2023, all revenues are classified as part of Net income from discontinued operations
Discontinued Operations	Discontinued Operations On April 20, 2023, the Company and Digipath Labs entered into an Asset Purchase Agreement (the “Purchase Agreement”) with DPL NV, LLC (“Buyer”), pursuant to which Digipath Labs agreed to sell substantially all of its assets to Buyer for a cash purchase price of $ 2,300,000 Assets and liabilities of the discontinued operations are aggregated and reported separately as assets and liabilities of discontinued operations in the Consolidated Balance Sheet as of September 30, 2023. On February 20, 2024, we completed the sale of the net assets of our subsidiary Digipath Labs and as such no longer have assets or liabilities that are reported separately in the Consolidated Balance Sheet as of March 31, 2024. The results of discontinued operations are aggregated and presented separately in the Consolidated Statements of Operations as net income from discontinued operations for the periods ended March 31, 2024 and 2023. The cash flows of the discontinued operations are reflected as cash flows of discontinued operations within the Company’s Consolidated Statements of Cash Flows for the periods ended March 31, 2024 and 2023. Amounts presented in discontinued operations have been derived from our consolidated financial statements and accounting records using the historical basis of assets, liabilities, results of operations, and cash flows of Digipath Labs. The discontinued operations exclude general corporate allocations.
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. The following table presents the effect of potential dilutive issuances for the three and six months ended March 31, 2024 and 2023: Schedule of Effect of Potential Dilutive Issuances March 31, 2024 March 31, 2023 March 31, 2024 March 31, 2023 Three Months Ended Six Months Ended March 31, 2024 March 31, 2023 March 31, 2024 March 31, 2023 Net income (loss) attributable to common stockholders $ (56,708 ) $ (121,821 ) $ (197,689 ) $ (360,694 ) Interest expense associated with convertible debt - - - - Net income (loss) for dilutive calculation $ (56,708 ) $ (121,821 ) (197,689 ) (360,694 ) Weighted average shares outstanding 92,083,084 82,296,820 89,576,328 82,257,534 Dilutive effect of preferred stock - - - - Dilutive effect of convertible debt - - - - Dilutive effect of common stock warrants - - - - Weighted average shares outstanding for diluted net income (loss) per share 92,083,084 82,296,820 89,576,328 82,257,534 For the three and six months ended March 31, 2024, potential dilutive securities of 104,490,131 8,120,000 15,387,050 13,579,710 For the three and six months ended March 31, 2023, potential dilutive securities of 83,125,488 shares issuable upon conversion of convertible notes payable, 6,020,000 15,387,050 shares issuable upon exercise of warrants, and 13,579,710 shares issuable upon conversion of our Preferred A and Preferred B shares, respectively, had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.
Reclassifications	Reclassifications Certain reclassifications have been made to the prior period financial statements to conform to the current period presentation. These reclassifications had no effect on our previously reported results of operations or accumulated deficit.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07 Segment Reporting ( Topic 280 Improvements to Reportable Segment Disclosures, In December 2023, the FASB issued ASU 2023-09 Income Taxes ( Topic 740 Improvements to Income Tax Disclosures,

Nature of Business and Signif_3

Nature of Business and Significant Accounting Policies (Tables)	6 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Schedule of Entities Under Common Control and Ownership	The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at March 31, 2024: Schedule of Entities Under Common Control and Ownership Jurisdiction of Name of Entity Incorporation Relationship Hypha Labs, Inc.(formerly Digipath, Inc.) (1) Nevada Parent Digipath Labs, Inc. Nevada Subsidiary Digipath Labs CA, Inc. (2) California Subsidiary Digipath Labs S.A.S. (3) Colombia Subsidiary VSSL Enterprises, Ltd. (4) Canada Subsidiary (1) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Hypha Labs, Inc., the parent company. (2) Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations. (3) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations. (4) Acquired on March 11, 2020.
Schedule of Effect of Potential Dilutive Issuances	The following table presents the effect of potential dilutive issuances for the three and six months ended March 31, 2024 and 2023: Schedule of Effect of Potential Dilutive Issuances March 31, 2024 March 31, 2023 March 31, 2024 March 31, 2023 Three Months Ended Six Months Ended March 31, 2024 March 31, 2023 March 31, 2024 March 31, 2023 Net income (loss) attributable to common stockholders $ (56,708 ) $ (121,821 ) $ (197,689 ) $ (360,694 ) Interest expense associated with convertible debt - - - - Net income (loss) for dilutive calculation $ (56,708 ) $ (121,821 ) (197,689 ) (360,694 ) Weighted average shares outstanding 92,083,084 82,296,820 89,576,328 82,257,534 Dilutive effect of preferred stock - - - - Dilutive effect of convertible debt - - - - Dilutive effect of common stock warrants - - - - Weighted average shares outstanding for diluted net income (loss) per share 92,083,084 82,296,820 89,576,328 82,257,534

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Summary of Financial Instruments at Fair Value on Recurring Basis	The Company has certain financial instruments that must be measured under the new fair value standard. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of March 31, 2024 and September 30, 2023, respectively: Summary of Financial Instruments at Fair Value on Recurring Basis Level 1 Level 2 Level 3 Fair Value Measurements at March 31, 2024 Level 1 Level 2 Level 3 Assets Cash $ 1,063,401 $ - $ - Liabilities Convertible notes payable, net of discounts of $ 0 - - 1,078,235 Level 1 Level 2 Level 3 Fair Value Measurements at September 30, 2023 Level 1 Level 2 Level 3 Assets Cash $ 271,006 $ - $ - Liabilities Notes payable - 565,000 - Convertible notes payable, net of discounts of $ 43,051 - - 1,725,184

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Schedule of Notes Payable	Notes payable consists of the following at March 31, 2024 and September 30, 2023, respectively: Schedule of Notes Payable March 31, 2024 September 30, 2023 On September 10, 2021, the Company issued a Secured Promissory note in the principal amount of $ 675,000 12 September 10, 2024 22,419.66 115,000 100,000 125,000 35,965 $ - $ 565,000 Total notes payable - 565,000 Less: current maturities - (565,000 ) Notes payable $ - $ - The Company recorded interest expense pursuant to the stated interest rate and closing costs on the notes payable in the amount of $ 36,614 24,000 Notes payable – discontinued operations On December 26, 2019, the Company financed the purchase of $ 377,124 291,931 5.75 5,622 five-year December 26, 2024 $ - $ 80,428

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	6 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Schedule of Related Party Convertible Notes Payable	Related party convertible notes payable consist of the following at March 31, 2024 and September 30, 2023, respectively: Schedule of Related Party Convertible Notes Payable March 31, 2024 September 30, 2023 On February 10, 2020, the Company completed the sale to an accredited investor of a 9% Secured Convertible Promissory Note in the principal amount of $ 350,000 August 10, 2022 9 0.15 0.03 50,000 400,000 50,000 1,666,667 0.03 February 11, 2024 4,550,000 43,788 As a result of the shares issued upon the extension agreement, the lender now holds more the 5% of the total outstanding common shares, and is therefore considered a related party $ - $ 350,000 Total related party convertible notes payable - 350,000 Less: unamortized debt discounts - (10,748 ) Total convertible debt - 339,252 Less: current maturities - (339,252 ) Related party convertible notes payable $ - $ -
Schedule of Convertible Notes Payable	Convertible notes payable consist of the following at March 31, 2024 and September 30, 2023, respectively: Schedule of Convertible Notes Payable March 31, 2024 September 30, 2023 On February 11, 2020, the Company completed the sale to an accredited investor of a 9% Secured Convertible Promissory Note in the principal amount of $ 50,000 August 11, 2022 9 0.15 0.03 10,000 60,000 10,000 333,334 0.03 February 11, 2024 650,000 6,989 $ 50,000 $ 50,000 On February 11, 2020, the Company completed the sale to an accredited investor of a 9% Secured Subordinated Convertible Promissory Note in the principal amount of $ 150,000 August 11, 2022 9 0.15 0.03 50,000 200,000 50,000 1,666,667 0.03 February 11, 2024 1,950,000 20,968 - 150,000 On September 23, 2019, the Company received proceeds of $ 200,000 8 August 10, 2022 0.11 August 10, 2022 0.03 90,000 3,000,000 0.03 355,469 98,188 February 11, 2024 4,621,105 32,166 February 11, 2025 0.01 481,955 355,469 355,469 On November 8, 2018, the Company received proceeds of $ 350,000 8 August 10, 2022 0.14 August 10, 2022 0.03 February 11, 2024 4,550,000 31,671 40,000 February 11, 2025 0.01 474,539 310,000 350,000 On October 1, 2022, the Company entered into a senior secured convertible note that carries an 8 February 11, 2024 362,765 0.01 4,715,945 30,102 362,765 362,765 On November 5, 2018, the Company received proceeds of $ 150,000 8 August 10, 2022 0.14 August 10, 2022 0.03 - 150,000 Total convertible notes payable 1,078,235 1,418,234 Less: unamortized debt discounts - (32,302 ) Total convertible debt 1,078,235 1,385,932 Less: current maturities (1,078,235 ) (1,385,932 ) Convertible notes payable $ - $ -
Schedule of Interest Expense	The Company recognized interest expense for the six months ended March 31, 2024 and 2023, respectively, as follows: Schedule of Interest Expense March 31, 2024 March 31, 2023 Interest on notes payable 36,614 29,770 Amortization of beneficial conversion features 43,050 77,616 Interest on convertible notes 78,607 72,473 Total interest expense $ 158,271 $ 179,859

Common Stock Options (Tables)

Common Stock Options (Tables)	6 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Summary of Common Stock Options Outstanding	The following is a summary of information about the stock options outstanding at March 31, 2024. Summary of Common Stock Options Outstanding Shares Underlying Options Outstanding Shares Underlying Options Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Options Contractual Exercise Options Exercise Prices Outstanding Life Price Exercisable Price $ 0.0056 0.13 8,120,000 4.53 $ 0.052 8,120,000 $ 0.052
Schedule of Activity of Outstanding Common Stock Options	The following is a summary of activity of outstanding common stock options: Schedule of Activity of Outstanding Common Stock Options Weighted Average Number Exercise of Shares Price Balance, September 30, 2023 8,120,000 $ 0.052 Options issued - - Options forfeited - - Balance, March 31, 2024 8,120,000 $ 0.052 Exercisable, March 31, 2024 8,120,000 $ 0.052

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	6 Months Ended
	Mar. 31, 2024
Common Stock Warrants
Summary of Common Stock Warrants Outstanding	The following is a summary of information about our warrants to purchase common stock outstanding at March 31, 2024 (including those issued to both investors and service providers). Summary of Common Stock Warrants Outstanding Shares Underlying Warrants Outstanding Shares Underlying Warrants Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Warrants Contractual Exercise Warrants Exercise Prices Outstanding Life Price Exercisable Price $ 0.0074 0.10 15,387,050 8.26 $ 0.016 15,387,050 $ 0.016
Schedule of Outstanding Common Stock Warrants Activity	The following is a summary of activity of outstanding common stock warrants: Schedule of Outstanding Common Stock Warrants Activity Weighted Average Number Exercise of Shares Price Balance, September 30, 2023 15,387,050 $ 0.016 Warrants granted - - Warrants expired - - Balance, March 31, 2024 15,387,050 $ 0.016 Exercisable, March 31, 2024 15,387,050 $ 0.016

Discontinued Operations (Tables

Discontinued Operations (Tables)	6 Months Ended
	Mar. 31, 2024
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Discontinued Operations of Income Statement and Balance Sheet Disclosures	The balance sheets of Digipath Labs are summarized below: Schedule of Discontinued Operations of Income Statement and Balance Sheet Disclosures March 31, 2024 September 30, 2023 Current assets: Accounts receivable, net $ - $ 447,410 Deposits - 18,675 Other current assets - 20,137 Total current assets - 486,222 Right-of-use asset - 274,985 Fixed assets, net - 368,681 Total long term assets - 643,666 Total Assets $ - $ 1,129,888 Current liabilities: Accounts payable $ - $ 158,869 Accrued expenses - 61,512 Current portion of operating lease liabilities - 83,757 Current maturities of notes payable - 64,517 Total current liabilities - 368,655 Operating lease liabilities - 143,245 Notes payable - 15,911 Total long term liabilities - 159,156 Total Liabilities $ - $ 527,811 The statements of operations of Digipath Labs combined are summarized below: 2024 2023 2024 2023 For the Three Months Ended For the Six Months Ended March 31, March 31 2024 2023 2024 2023 Revenues $ 712,145 $ 760,710 $ 1,635,299 $ 1,487,465 Cost of sales 229,013 459,608 650,524 882,443 Gross profit 483,132 301,102 984,775 605,022 Operating expenses: General and administrative 189,983 224,346 393,168 504,990 Professional fees - 20,688 4,750 43,460 Total operating expenses 189,983 245,034 397,918 548,450 Operating income(loss) 293,149 56,068 586,857 56,572 Other income (expense): Interest expense (620 ) (1,745 ) (1,701 ) (3,706 ) Total other income (expense) (620 ) (1,745 ) (1,701 ) (3,706 ) Net income (loss) $ 292,529 $ 54,323 $ 585,156 $ 52,866

Schedule of Entities Under Comm

Schedule of Entities Under Common Control and Ownership (Details)	6 Months Ended
	Mar. 31, 2024
Entities Under Common Control and Ownership One [Member]
Name of Entity	Hypha Labs, Inc.(formerly Digipath, Inc.)	[1]
Jurisdiction of Incorporation	Nevada	[1]
Relationship	Parent	[1]
Entities Under Common Control and Ownership Two [Member]
Name of Entity	Digipath Labs, Inc.
Jurisdiction of Incorporation	Nevada
Relationship	Subsidiary
Entities Under Common Control and Ownership Three [Member]
Name of Entity	Digipath Labs CA, Inc.	[2]
Jurisdiction of Incorporation	California	[2]
Relationship	Subsidiary	[2]
Entities Under Common Control and Ownership Four [Member]
Name of Entity	Digipath Labs S.A.S.	[3]
Jurisdiction of Incorporation	Colombia	[3]
Relationship	Subsidiary	[3]
Entities Under Common Control and Ownership Five [Member]
Name of Entity	VSSL Enterprises, Ltd.	[4]
Jurisdiction of Incorporation	Canada	[4]
Relationship	Subsidiary	[4]
[1]Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Hypha Labs, Inc., the parent company.[2]Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations.[3]Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations.[4]Acquired on March 11, 2020.

Schedule of Effect of Potential

Schedule of Effect of Potential Dilutive Issuances (Details) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Accounting Policies [Abstract]
Net income (loss) attributable to common stockholders	$ (56,708)	$ (121,821)	$ (197,689)	$ (360,694)
Interest expense associated with convertible debt
Net income (loss) for dilutive calculation	$ (56,708)	$ (121,821)	$ (197,689)	$ (360,694)
Weighted average shares outstanding	92,083,084	82,296,820	89,576,328	82,257,534
Dilutive effect of preferred stock
Dilutive effect of convertible debt
Dilutive effect of common stock warrants
Weighted average shares outstanding for diluted net income (loss) per share	92,083,084	82,296,820	89,576,328	82,257,534

Nature of Business and Signif_4

Nature of Business and Significant Accounting Policies (Details Narrative) - USD ($)		3 Months Ended		6 Months Ended
	Apr. 20, 2023	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Schedule of Equity Method Investments [Line Items]
Cash purchase price					$ 235,000
Conversion of Stock, Shares Issued				8,340,000
Series A Convertible Preferred Stock [Member]
Schedule of Equity Method Investments [Line Items]
Conversion of Stock, Shares Issued		13,579,710	13,579,710	13,579,710	13,579,710
Series B Convertible Preferred Stock [Member]
Schedule of Equity Method Investments [Line Items]
Conversion of Stock, Shares Issued		13,579,710	13,579,710	13,579,710	13,579,710
Convertible Debt Securities [Member]
Schedule of Equity Method Investments [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		104,490,131	83,125,488	104,490,131	83,125,488
Share-Based Payment Arrangement, Option [Member]
Schedule of Equity Method Investments [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		8,120,000	6,020,000	8,120,000	6,020,000
Warrant [Member]
Schedule of Equity Method Investments [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		15,387,050	15,387,050	15,387,050	15,387,050
Discontinued Operations, Held-for-Sale [Member] | Purchase Agreement [Member]
Schedule of Equity Method Investments [Line Items]
Cash purchase price	$ 2,300,000

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	Mar. 31, 2024	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Working Capital	$ 138,061
Accumulated deficit	19,374,530	$ 19,761,997
Cash	$ 1,063,401	$ 271,006

Summary of Financial Instrument

Summary of Financial Instruments at Fair Value on Recurring Basis (Details) - USD ($)	Mar. 31, 2024	Sep. 30, 2023
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash	$ 1,063,401	$ 271,006
Convertible notes payable, net of discounts of $43,051
Notes payable
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash
Convertible notes payable, net of discounts of $43,051
Notes payable		565,000
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash
Convertible notes payable, net of discounts of $43,051	$ 1,078,235	1,725,184
Notes payable

Summary of Financial Instrume_2

Summary of Financial Instruments at Fair Value on Recurring Basis (Details) (Parenthetical) - USD ($)	Mar. 31, 2024	Sep. 30, 2023
Convertible Debt [Member]
Short-Term Debt [Line Items]
Convertible notes discounts	$ 0	$ 43,051

Related Party Transactions (Det

Related Party Transactions (Details Narrative)	6 Months Ended
	Mar. 31, 2024 USD ($)
Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Service for incurred fees	$ 30,000
Board of Directors [Member]
Related Party Transaction [Line Items]
Service for incurred fees	10,000
Due to related party	$ 20,000

Note Receivable (Details Narrat

Note Receivable (Details Narrative) - USD ($)

Dec. 31, 2025

Sep. 30, 2025

Jun. 30, 2025

Mar. 31, 2025

Dec. 31, 2024

Sep. 30, 2024

Jun. 30, 2024

Mar. 31, 2024

Dec. 31, 2023

Sep. 30, 2023

Jun. 30, 2023

Dec. 08, 2022

Sep. 30, 2022

Jun. 13, 2019

Financing Receivable, Modified [Line Items]

Purchase price note receivable

Asset Purchase Agreement [Member] | Invictus Wealth Group [Member]

Financing Receivable, Modified [Line Items]

Debt instrument stated percentage

10%

Purchase price note receivable

$ 900,000

Upfront payment

275,000

Purchase price note receivable

$ 625,000

Debt instrument maturity date

Dec. 31, 2023

Debt final payment

$ 425,000

100,000

$ 100,000

Received portion of upfront payment

$ 275,000

Asset Purchase Agreement [Member] | Invictus Wealth Group [Member] | Extended Maturity [Member]

Financing Receivable, Modified [Line Items]

Debt final payment

$ 50,000

$ 50,000

$ 50,000

$ 425,000

$ 100,000

$ 100,000

Asset Purchase Agreement [Member] | Invictus Wealth Group [Member] | Extended Maturity [Member] | Forecast [Member]

Financing Receivable, Modified [Line Items]

Debt final payment

$ 216,780

$ 125,000

$ 100,000

$ 100,000

Northwest Analytical Labs, Inc. [Member]

Financing Receivable, Modified [Line Items]

Notes receivable

$ 95,000

Debt instrument stated percentage

10%

C3 Labs, Inc., [Member]

Financing Receivable, Modified [Line Items]

Notes receivable

$ 1,056,570

Debt instrument stated percentage

8%

Interest receivable

$ 64,017

Schedule of Notes Payable (Deta

Schedule of Notes Payable (Details) - USD ($)	Mar. 31, 2024	Sep. 30, 2023
Short-Term Debt [Line Items]
Total notes payable		$ 565,000
Less: current maturities		(565,000)
Notes payable
Notes Payable [Member]
Short-Term Debt [Line Items]
Total notes payable		565,000
Notes Payable [Member] | Discontinued Operations [Member]
Short-Term Debt [Line Items]
Total notes payable		$ 80,428

Schedule of Notes Payable (De_2

Schedule of Notes Payable (Details) (Parenthetical) - USD ($)			3 Months Ended	6 Months Ended		12 Months Ended
	Sep. 10, 2021	Dec. 26, 2019	Dec. 31, 2023	Mar. 31, 2024	Mar. 31, 2023	Sep. 30, 2023	Sep. 30, 2022
Short-Term Debt [Line Items]
Repayments of notes payable				$ 595,965
Canna Lab Note [Member]
Short-Term Debt [Line Items]
Additional debt amount	$ 675,000
Debt instrument stated percentage	12%
Debt instrument, maturity date	Sep. 10, 2024
Debt instrument periodic payment	$ 22,419.66
Secured Promissory Note [Member]
Short-Term Debt [Line Items]
Additional debt amount							$ 115,000
Repayments of notes payable						$ 100,000	$ 125,000
Accrued interest			$ 35,965
Note Payable [Member]
Short-Term Debt [Line Items]
Interest expense				$ 36,614	$ 24,000
Note Payable [Member] | Discontinued Operations [Member]
Short-Term Debt [Line Items]
Debt instrument stated percentage		5.75%
Debt instrument, maturity date		Dec. 26, 2024
Debt instrument periodic payment		$ 5,622
Payments for lab equipment		377,124
Proceeds from bank loan		$ 291,931
Debt instrument term description		5 years

Schedule of Related Party Conve

Schedule of Related Party Convertible Notes Payable (Details) - USD ($)	Mar. 31, 2024	Sep. 30, 2023
Short-Term Debt [Line Items]
Total related party convertible notes payable	$ 1,078,235	$ 1,418,234
Total convertible debt	1,078,235	1,385,932
Less: current maturities	(1,078,235)	(1,385,932)
Related Party [Member]
Short-Term Debt [Line Items]
Total related party convertible notes payable		350,000
Less: unamortized debt discounts		(10,748)
Total convertible debt		339,252
Less: current maturities		(339,252)
Related party convertible notes payable
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Less: unamortized debt discounts	0
Convertible Notes Payable [Member] | Related Party [Member]
Short-Term Debt [Line Items]
Total related party convertible notes payable		$ 350,000

Schedule of Related Party Con_2

Schedule of Related Party Convertible Notes Payable (Details) (Parenthetical) - Secured Subordinated Convertible Promissory Note [Member] - Accredited Investors [Member] - USD ($)	Aug. 08, 2022	Dec. 29, 2020	Dec. 28, 2020	Feb. 10, 2020
Short-Term Debt [Line Items]
Principal amount		$ 50,000	$ 400,000	$ 350,000
Maturity date	Feb. 11, 2024			Aug. 10, 2022
Debt instrument interest percentage				9%
Conversion price		$ 0.03	$ 0.03	$ 0.15
Proceeds from convertible debt			$ 50,000
Debt converted principal value, shares		1,666,667
Shares of common stock issued	4,550,000
Debt instrument fair value	$ 43,788
Debt instrument agreement	As a result of the shares issued upon the extension agreement, the lender now holds more the 5% of the total outstanding common shares, and is therefore considered a related party

Schedule of Convertible Notes P

Schedule of Convertible Notes Payable (Details) - USD ($)	Mar. 31, 2024	Sep. 30, 2023
Short-Term Debt [Line Items]
Total convertible notes payable	$ 1,078,235	$ 1,418,234
Less: unamortized debt discounts		(32,302)
Total convertible debt	1,078,235	1,385,932
Less: current maturities	(1,078,235)	(1,385,932)
Nonrelated Party [Member]
Short-Term Debt [Line Items]
Convertible notes payable
Convertible Notes Payable One [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	50,000	50,000
Convertible Notes Payable Two [Member]
Short-Term Debt [Line Items]
Total convertible notes payable		150,000
Convertible Notes Payable Three [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	355,469	355,469
Convertible Notes Payable Four [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	310,000	350,000
Convertible Notes Payable Five [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	362,765	362,765
Convertible Notes Payable Six [Member]
Short-Term Debt [Line Items]
Total convertible notes payable		$ 150,000

Schedule of Convertible Notes_2

Schedule of Convertible Notes Payable (Details) (Parenthetical) - USD ($)

3 Months Ended

6 Months Ended

12 Months Ended

Jan. 29, 2024

Jan. 22, 2024

Oct. 02, 2022

Aug. 08, 2022

Sep. 30, 2021

Feb. 22, 2021

Dec. 29, 2020

Dec. 28, 2020

Sep. 30, 2020

Aug. 08, 2020

Feb. 11, 2020

Sep. 23, 2019

Nov. 08, 2018

Nov. 05, 2018

Mar. 31, 2024

Mar. 31, 2023

Mar. 31, 2024

Mar. 31, 2023

Sep. 30, 2022

Short-Term Debt [Line Items]

Amortization of debt discount premium

$ 43,050

$ 77,616

Debt instrument purchase of warrant

15,387,050

15,387,050

Loss on debt extinguishment

$ (956,494)

$ (956,494)

9% Secured Convertible Promissory Note [Member] | Accredited Investors [Member]

Short-Term Debt [Line Items]

Principal amount

$ 10,000

$ 60,000

$ 50,000

Maturity date

Feb. 11, 2024

Aug. 11, 2022

Debt instrument interest percentage

9%

Conversion price

$ 0.03

$ 0.03

$ 0.15

Proceeds from convertible debt

$ 10,000

Debt converted principal value, shares

333,334

Shares issued in exchange of extension

650,000

Debt instrument fair value

$ 6,989

9% Secured Subordinated Convertible Promissory Note [Member] | Accredited Investors [Member]

Short-Term Debt [Line Items]

Principal amount

$ 200,000

$ 150,000

Maturity date

Feb. 11, 2024

Aug. 11, 2022

Debt instrument interest percentage

9%

Conversion price

$ 0.03

$ 0.03

$ 0.15

Proceeds from convertible debt

$ 50,000

Debt converted principal value, shares

1,666,667

Debt converted principal amount

$ 50,000

9% Secured Subordinated Convertible Promissory Note [Member] | Accredited Investors One [Member]

Short-Term Debt [Line Items]

Shares issued in exchange of extension

1,950,000

Debt instrument fair value

$ 20,968

Senior Secured Convertible Note [Member]

Short-Term Debt [Line Items]

Maturity date

Feb. 11, 2025

Feb. 11, 2024

Aug. 10, 2022

Aug. 10, 2022

Debt instrument interest percentage

8%

Conversion price

$ 0.01

$ 0.03

$ 0.03

$ 0.11

Proceeds from convertible debt

$ 200,000

Debt converted principal value, shares

3,000,000

Debt converted principal amount

$ 90,000

Debt instrument periodic payment

$ 355,469

Amortization of debt discount premium

$ 98,188

Debt instrument purchase of warrant

4,621,105

Debt instrument fair value of warrant

$ 32,166

Loss on debt extinguishment

$ 481,955

Senior Secured Convertible Note One [Member]

Short-Term Debt [Line Items]

Maturity date

Feb. 11, 2025

Feb. 11, 2024

Aug. 10, 2022

Aug. 10, 2022

Debt instrument interest percentage

8%

Conversion price

$ 0.01

$ 0.03

$ 0.14

Proceeds from convertible debt

$ 350,000

Debt instrument purchase of warrant

4,550,000

Debt instrument fair value of warrant

$ 31,671

Loss on debt extinguishment

$ 474,539

Conversion of notes payable into common stock value

$ 40,000

Senior Secured Convertible Note Two [Member]

Short-Term Debt [Line Items]

Maturity date

Feb. 11, 2024

Debt instrument interest percentage

8%

Conversion price

$ 0.01

Debt instrument purchase of warrant

4,715,945

Debt instrument fair value of warrant

$ 30,102

Debt conversion original debt amount

$ 362,765

Senior Secured Convertible Note Three [Member]

Short-Term Debt [Line Items]

Maturity date

Aug. 10, 2022

Aug. 10, 2022

Debt instrument interest percentage

8%

Conversion price

$ 0.03

$ 0.14

Proceeds from convertible debt

$ 150,000

Schedule of Interest Expense (D

Schedule of Interest Expense (Details) - USD ($)	6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Debt Disclosure [Abstract]
Interest on notes payable	$ 36,614	$ 29,770
Amortization of beneficial conversion features	43,050	77,616
Interest on convertible notes	78,607	72,473
Total interest expense	$ 158,271	$ 179,859

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2024	Mar. 31, 2023	Sep. 30, 2023
Short-Term Debt [Line Items]
Amortization of debt discounts			$ 43,050	$ 77,616
Maximum Share Amount [Member]
Short-Term Debt [Line Items]
Maximum amount owned percentage of issued and outstanding common shares			4.99%
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Debt discount conversion feature of convertible debt					$ 93,938
Amortization of debt discounts			$ 43,050	$ 77,616
Unamortized discounts			$ 0
Convertible notes interest expense	$ 77,808	$ 72,473

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended
	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2022	Jul. 20, 2022
Class of Stock [Line Items]
Preferred stock, shares authorized	10,000,000				10,000,000
Preferred stock, par or stated value per share	$ 0.001				$ 0.001
Common stock, shares authorized	250,000,000				250,000,000	250,000,000
Common stock, par value	$ 0.001				$ 0.001	$ 0.001
Common stock, shares issued	105,280,155				105,280,155	87,096,820
Common stock, shares outstanding	105,280,155				105,280,155	87,096,820
Conversion of convertible note payables into common stock value
Common Stock [Member]
Class of Stock [Line Items]
Conversion of convertible note payables into common shares				7,150,000	4,000,000
Conversion of convertible note payables into common stock value				$ 7,150	$ 40,000
Shares of stock-based compensation	14,183,335				14,183,335
Stock issuance for aggregate value					$ 348,331
Common Stock [Member] | Director [Member]
Class of Stock [Line Items]
Shares of stock-based compensation					6,000,000
Stock issued value related to directors					$ 112,200
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized	6,000,000				6,000,000	6,000,000
Preferred stock, par or stated value per share	$ 0.001				$ 0.001	$ 0.001
Preferred stock, shares outstanding	1,047,942				1,047,942	1,047,942
Preferred stock, shares outstanding	1,047,942				1,047,942	1,047,942
Series A Convertible Preferred Stock [Member] | Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares outstanding	1,047,942				1,047,942
Preferred stock, shares outstanding	1,047,942				1,047,942
Conversion of convertible note payables into common stock value
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Temporary equity, shares authorized	1,500,000				1,500,000	1,500,000
Temporary equity, shares issued	333,600				333,600	333,600
Temporary equity, shares outstanding	333,600				333,600	333,600
Series B Convertible Preferred Stock [Member] | Preferred Stock [Member]
Class of Stock [Line Items]
Temporary equity, shares issued	333,600				333,600
Temporary equity, shares outstanding	333,600	333,600	333,600	333,600	333,600	333,600	333,600
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized	1,000				1,000
Preferred stock, par or stated value per share								$ 1
Preferred stock, shares designated remaining	2,499,000				2,499,000
Preferred stock voting rights					the Company’s common stock on all matters presented to the holders of common stock, whether at a special or annual meeting, by written action in lieu of a meeting or otherwise, on the basis of 200,000 votes for each share of Series C Preferred Stock
Preferred stock voting rights	$ 0.10				$ 0.10
Conversion of stock description					Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, or upon a change in control whereby a stockholder gains control of 50% or more of the outstanding shares of common stock, the shares of Series C Preferred are entitled to receive, prior to any distribution to the holders of common stock, 100% of the stated value per share of Series C Preferred.
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized	1,000				1,000	1,000
Preferred stock, par or stated value per share	$ 0.001				$ 0.001	$ 0.001
Preferred stock, shares outstanding	0				0	0
Preferred stock, shares outstanding	0				0	0
Series C Convertible Preferred Stock [Member] | Preferred Stock [Member]
Class of Stock [Line Items]
Temporary equity, shares issued	0				0
Temporary equity, shares outstanding	0				0
Conversion of convertible note payables into common stock value
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Conversion of stock, shares converted					1,047,942
Convertible shares	5,239,710				5,239,710
Common stock, terms of conversion					No holder is permitted to convert its shares of Series A Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice.
Percentage of distribution on purchase price	100%				100%
Series A Preferred Stock [Member] | Noteholders [Member]
Class of Stock [Line Items]
Percentage of equity beneficial ownership	4.99%				4.99%

Mezzanine Equity (Details Narra

Mezzanine Equity (Details Narrative)	6 Months Ended
	Mar. 31, 2024 $ / shares shares
Preferred stock, par value	$ 0.001
Conversion of stock shares issued | shares	8,340,000
Series B Preferred Stock [Member]
Preferred stock, par value	$ 1
Conversion price	$ 0.04
Conversion shares converted | shares	333,600
Common stock, terms of conversion	No holder is permitted to convert its shares of Series B Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice
Conversion of stock description	Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, or upon a change in control whereby a stockholder gains control of 50% or more of the outstanding shares of common stock, the shares of Series B Preferred are entitled to receive, prior to any distribution to the holders of common stock and Series A Preferred, 100% of the purchase price per share of Series B Preferred plus all accrued but unpaid dividends

Summary of Common Stock Options

Summary of Common Stock Options Outstanding (Details)	6 Months Ended
	Mar. 31, 2024 $ / shares shares
Share-Based Payment Arrangement [Abstract]
Range of Exercise Price, Minimum	$ 0.0056
Range of Exercise Price, Maximum	$ 0.13
Number of Options Outstanding | shares	8,120,000
Weighted Average Remaining Contractual Life	4 years 6 months 10 days
Weighted Average Exercise Price	$ 0.052
Number of Shares Exercisable | shares	8,120,000
Weighted Average Exercise Price Exercisable	$ 0.052

Schedule of Activity of Outstan

Schedule of Activity of Outstanding Common Stock Options (Details)	6 Months Ended
	Mar. 31, 2024 $ / shares shares
Share-Based Payment Arrangement [Abstract]
Number of Shares Outstanding, Beginning balance | shares	8,120,000
Weighted Average Exercise Price, Outstanding, Beginning | $ / shares	$ 0.052
Number of Shares Options issued | shares
Weighted Average Exercise Price, Options issued | $ / shares
Number of Shares Options forfeited | shares
Weighted Average Exercise Price, Options forfeited | $ / shares
Number of Shares Outstanding, Ending balance | shares	8,120,000
Weighted Average Exercise Price, Outstanding, Ending | $ / shares	$ 0.052
Number of Shares Exercisable, Ending | shares	8,120,000
Weighted Average Exercise Price, Exercisable, Ending | $ / shares	$ 0.052

Common Stock Options (Details N

Common Stock Options (Details Narrative) - USD ($)		6 Months Ended
	Jun. 21, 2016	Mar. 31, 2024	Mar. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Intrinsic value, outstanding		$ 33,600
Market price, per share		$ 0.022
Amortization of Stock Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expenses		$ 1,153	$ 17,510
Unamortized expenses expected to be expensed		$ 0
2012 Stock Incentive Plan [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares issued under stock plan	11,500,000

Summary of Common Stock Warrant

Summary of Common Stock Warrants Outstanding (Details)	6 Months Ended
	Mar. 31, 2024 $ / shares shares
Common Stock Warrants
Exercise Price Range Lower Range	$ 0.0074
Exercise Price Range Upper Range	$ 0.10
Number of Warrants Outstanding | shares	15,387,050
Weighted Average Remaining Contractual Life	8 years 3 months 3 days
Weighted Average Exercise Price	$ 0.016
Number of Warrants Exercisable | shares	15,387,050
Weighted Average Exercise Price, Exercisable	$ 0.016

Schedule of Outstanding Common

Schedule of Outstanding Common Stock Warrants Activity (Details)	6 Months Ended
	Mar. 31, 2024 $ / shares shares
Common Stock Warrants
Number of Shares, Balance beginning | shares	15,387,050
Weighted Average Exercise Price, Balance beginning	$ 0.016
Number of Shares, Warrants granted | shares
Weighted Average Exercise Price, Warrants granted
Number of Shares, Warrants expired | shares
Weighted Average Exercise Price, Warrants expired
Number of Shares, Balance ending | shares	15,387,050
Weighted Average Exercise Price, Balance, ending	$ 0.016
Number of Shares, Exercisable	15,387,050
Weighted Average Exercise Price, Exercisable	$ 0.016

Common Stock Warrants (Details

Common Stock Warrants (Details Narrative)	6 Months Ended
	Mar. 31, 2024 USD ($) $ / shares shares
Number of warrant to purchase of common stock shares | shares	15,387,050
Warrant [Member]
Warrants, intrinic value | $	$ 197,196
Intrinsic value, market price per share | $ / shares	$ 0.02

Schedule of Discontinued Operat

Schedule of Discontinued Operations of Income Statement and Balance Sheet Disclosures (Details) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023	Sep. 30, 2023
Current assets:
Accounts receivable, net					$ 447,410
Deposits					18,675
Other current assets					20,137
Total current assets					486,222
Right-of-use asset					274,985
Fixed assets, net					368,681
Total long term assets					643,666
Total Assets					1,129,888
Current liabilities:
Accounts payable					158,869
Accrued expenses					61,512
Current portion of operating lease liabilities					83,757
Current maturities of notes payable					64,517
Total current liabilities					368,655
Operating lease liabilities					143,245
Notes payable					15,911
Total long term liabilities					159,156
Total Liabilities					$ 527,811
Revenues	712,145	$ 760,710	1,635,299	$ 1,487,465
Cost of sales	229,013	459,608	650,524	882,443
Gross profit	483,132	301,102	984,775	605,022
Operating expenses:
General and administrative	189,983	224,346	393,168	504,990
Professional fees		20,688	4,750	43,460
Total operating expenses	189,983	245,034	397,918	548,450
Operating income(loss)	293,149	56,068	586,857	56,572
Other income (expense):
Interest expense	(620)	(1,745)	(1,701)	(3,706)
Total other income (expense)	(620)	(1,745)	(1,701)	(3,706)
Net income (loss)	$ 292,529	$ 54,323	$ 585,156	$ 52,866

Discontinued Operations (Detail

Discontinued Operations (Details Narrative) - USD ($)				3 Months Ended		6 Months Ended
	Feb. 20, 2024	Apr. 30, 2023	Apr. 20, 2023	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash purchase price							$ 235,000
Working capital				$ (138,061)		(138,061)
Gain on sale of subsidiary net assets	$ 1,596,505			$ 1,596,505		$ 1,596,505
Purchase Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Working capital			$ 150,000
Escrow deposits			230,000
Management Services Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Description of collaborative arrangement		The effectiveness of the Management Services Agreement was subject to the approval of the CCB, which was obtained on October 17, 2023. Pursuant to the Management Services Agreement, after the payment of expenses to third parties and a payment of 15% of cash collections to Digipath (but not less than $15,000) in each month, Buyer was entitled to a management fee of $10,000 per month. Any remaining cash generated from the operation of the Lab in any month was payable 45% to the Buyer and 55% to the Company.
Discontinued Operations, Held-for-Sale [Member] | Purchase Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash purchase price			$ 2,300,000